Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorGiovanna Zamboni

About this trial

The goal of this trial is to learn whether home-based robotic interventions can reduce apathy in people with cognitive decline. Apathy means reduced motivation, interest, or initiative in daily life. It is a common and distressing symptom in people with mild cognitive impairment (MCI) or dementia and can strongly affect both participants and their caregivers.

This study will compare two different robotic interventions with standard occupational therapy. Researchers want to understand if these new technologies can help people become more engaged, motivated, and involved in everyday activities, and whether they also reduce stress and improve quality of life for caregivers.

The main questions this study aims to answer are:

* Do robotic interventions reduce apathy more than standard occupational therapy? * Are these robotic interventions easy to use and acceptable for people with cognitive impairment? * Do these interventions reduce caregiver stress and improve caregiver quality of life?

Participants will be adults over 40 years of age with a diagnosis of mild cognitive impairment or dementia caused by a neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, or dementia with Lewy bodies. All participants must show clinically relevant apathy and have a family member or caregiver who can support them during the study and answer questionnaires.

Participants will be randomly assigned to one of three groups:

* A telepresence robot group, where participants interact at home with a therapist through a remotely controlled robot that delivers personalized cognitive stimulation. * A social robot group, where participants interact at home with a humanoid robot that holds personalized conversations on topics of interest. * A control group receiving home-based occupational therapy, which is the current standard care for behavioral symptoms.

Each intervention lasts six weeks and takes place in the participant's home. The robotic interventions are designed to fit into daily routines and can be adapted to the participant's abilities and preferences. Occupational therapy sessions focus on meaningful activities, environmental adaptations, and caregiver support.

Participants will complete assessments at three time points: before the intervention, at the end of the six-week intervention, and eight weeks after the intervention ends. These assessments include interviews, questionnaires, and simple tasks to measure apathy, emotional responses, social interaction, and quality of life. Caregivers will also complete questionnaires about stress and daily burden.

Researchers will also collect information about how often and how participants interact with the robots, such as how long conversations last and how engaged participants appear. These data will help researchers understand how robotic interactions relate to changes in apathy and behavior.

This study aims to provide evidence on whether robotic technologies can be safely and effectively used at home to support people with cognitive impairment and apathy. The results may help develop new non-drug treatments and improve care options for people living with dementia and their caregivers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 40 years or older

Clinical diagnosis of a neurocognitive disorder, including: Mild cognitive impairment (MCI) or mild behavioral impairment (MBI), or Major neurocognitive disorder (dementia), due to Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, or other neurodegenerative diseases.

Presence of clinically relevant apathy, defined as a score greater than 2 on the apathy domain (G) of the Neuropsychiatric Inventory (NPI).

Preserved ability to understand and produce spoken and written language sufficient to participate in the intervention and assessments.

Disqualifiers

Refusal or withdrawal of informed consent by the participant or the study partner.

History or current evidence of neurological conditions other than the target neurodegenerative diseases that may affect cognitive function (e.g., major stroke, brain tumor, normal pressure hydrocephalus, traumatic brain injury).

History or current diagnosis of major psychiatric disorders that could interfere with study participation or assessments.

Presence of medical conditions that may significantly affect cognitive function (e.g., severe renal or hepatic failure, untreated obstructive sleep apnea, hypothyroidism, vitamin B12 deficiency).

Trial design

Design model

Parallel

Treatments tested in this trial

  • telepresence robotic system

    Device

    The telepresence robot is designed to enable high-quality remote interaction through high-definition video streaming, clear two-way audio, and intuitive mobile navigation. It allows a therapist to connect in real time with a participant at home, moving within the environment and interacting as if physically present. In the RAPHAEL study, the telerobot is used by an occupational therapist to deliver personalized home-based sessions, guiding participants through exercises and activities via video calls conducted from the therapist's own device. The robot operates according to the manufacturer's intended use and user manual. Its modular hardware and software, reliability, and ease of use support consistent delivery of intervention sessions. The telerobot is already widely used in healthcare, education, and professional settings in more than 30 countries, making it a well-established platform for remote clinical interaction and support.

  • Pepper robot connected to a CAIR server

    Device

    The intervention is based on an integrated robotic system designed to support personalized social interaction at home. It includes a commercial humanoid robot (Pepper) used as a physical interaction platform, supported by a local computer server and a Wi-Fi router with 4G connectivity to ensure stable operation. The core of the intervention is a dedicated software medical device (Server CAIR), which manages and adapts the interaction logic. A client application running on the robot enables verbal and non-verbal communication with the participant, while a separate software interface allows researchers to personalize content based on individual preferences and history. Speech recognition and language processing are supported by third-party services for voice transcription and response generation. Together, these components enable adaptive, conversational interactions aimed at stimulating engagement and social participation in a home setting.

  • Occupational Therapy

    Behavioral

    Human-based intervention delivered through an occupational therapy program focused on the prevention and management of behavioral symptoms, conducted by an occupational therapist in accordance with Essential Levels of Care (LEA). The techniques and protocols aim to prevent, reduce, and manage BPSD, train the caregiver, and improve quality of life for both the individual and the caregiver. The intervention includes 8 home visits and 2 telephone sessions over 6 weeks.

Treatment groups

75 Participants
are divided into 3 treatment groups
Group A: telepresence robotExperimental treatment 1 intervention
Group B: social robotExperimental treatment 1 intervention
Group C: occupational therapyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in apathy severity

Change in apathy severity measured by the Apathy Evaluation Scale (AES) total score, assessed from baseline (T0) to end of intervention at 6 weeks (T1).

Time frame
Baseline to 6 weeks

Secondary outcomes

1

Caregiver burden

Change in caregiver burden measured by the Zarit Burden Inventory (ZBI) total score.

Time frame
Baseline, 6 weeks
2

caregiver quality of life

Change in caregiver quality of life measured by the Quality of Life-Alzheimer's Disease (QoL-AD) caregiver version

Time frame
Baseline, 6 weeks
3

social cognition

Change in social cognition performance measured by the Yoni-48 task and the Edinburgh Social Cognition Test (ESCoT).

Time frame
0 to 6 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Giovanna Zamboni

Lead sponsor

University of Modena and Reggio Emilia

Sponsor institution

University of Genova

Collaborator

Fondazione Don Carlo Gnocchi Onlus

Collaborator

University of Florence

Collaborator